Neumora Therapeutics (NMRA) Return on Capital Employed (2023 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Return on Capital Employed of 156.72% for Q1 2026, down 5059.0% year-over-year from 3.16% in Q1 2025, and up 1.23% quarter-over-quarter from 158.67% in Q4 2025.
Neumora Therapeutics (NMRA) Return on Capital Employed (2023 - 2026) Analysis & Trends
Neumora Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 156.72% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5059.0% year-over-year to 156.72%; the TTM figure through Mar 2026 stood at 156.72% (down 5059.0% YoY), while the FY2025 annual figure was 108.85%, down 3890.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 156.72%, up from 158.67% in the prior quarter.
- The five-year high for Return on Capital Employed was 50.89% in Q4 2023, with the low at 158.67% in Q4 2025.
- The 4-year median for Return on Capital Employed is 98.42% (2024), against an average of 104.44%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 3553 bps in 2024, then plunged 7225 bps in 2025.
- Neumora Therapeutics' Return on Capital Employed stood at 50.89% in 2023, then sank by 70 bps to 86.42% in 2024, then sank by 84 bps to 158.67% in 2025, then increased by 1 bps to 156.72% in 2026.
- Business Quant data shows NMRA's Return on Capital Employed at 156.72% in Q1 2026, 158.67% in Q4 2025, and 140.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -156.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -156.72% |
| Dec 31, 2025 | -158.67% |
| Sep 30, 2025 | -140.35% |
| Jun 30, 2025 | -120.72% |
| Mar 31, 2025 | -106.13% |
| Dec 31, 2024 | -86.42% |
| Sep 30, 2024 | -90.71% |
| Jun 30, 2024 | -72.92% |
| Mar 31, 2024 | -60.86% |
| Dec 31, 2023 | -50.89% |